Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2016 - 2026)

Amphastar Pharmaceuticals has reported Cash & Equivalents over the past 13 years, most recently at $170.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 12.25% year-over-year to $170.2 million; the TTM value through Dec 2025 reached $170.2 million, up 12.25%, while the annual FY2025 figure was $170.2 million, 12.25% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $170.2 million at Amphastar Pharmaceuticals, down from $216.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $266.8 million in Q3 2023 and troughed at $101.6 million in Q1 2021.
  • A 5-year average of $166.0 million and a median of $168.2 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 85.25% in 2021 and later fell 27.99% in 2024.
  • Year by year, Cash & Equivalents stood at $126.4 million in 2021, then increased by 23.54% to $156.1 million in 2022, then decreased by 7.56% to $144.3 million in 2023, then rose by 5.07% to $151.6 million in 2024, then increased by 12.25% to $170.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for AMPH at $170.2 million in Q4 2025, $216.3 million in Q3 2025, and $187.7 million in Q2 2025.